These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 28784564)
1. Cell-Free DNA-Based Non-invasive Prenatal Screening for Common Aneuploidies in a Canadian Province: A Cost-Effectiveness Analysis. Nshimyumukiza L; Beaumont JA; Duplantie J; Langlois S; Little J; Audibert F; McCabe C; Gekas J; Giguère Y; Gagné C; Reinharz D; Rousseau F J Obstet Gynaecol Can; 2018 Jan; 40(1):48-60. PubMed ID: 28784564 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review. García-Pérez L; Linertová R; Álvarez-de-la-Rosa M; Bayón JC; Imaz-Iglesia I; Ferrer-Rodríguez J; Serrano-Aguilar P Eur J Health Econ; 2018 Sep; 19(7):979-991. PubMed ID: 29249015 [TBL] [Abstract][Full Text] [Related]
3. Economic analysis of prenatal screening strategies for Down syndrome in singleton pregnancies in Turkey. Ökem ZG; Örgül G; Kasnakoglu BT; Çakar M; Beksaç MS Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():40-44. PubMed ID: 29040895 [TBL] [Abstract][Full Text] [Related]
4. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis. Fairbrother G; Burigo J; Sharon T; Song K J Matern Fetal Neonatal Med; 2016; 29(7):1160-4. PubMed ID: 26000626 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis. Zhang W; Mohammadi T; Sou J; Anis AH PLoS One; 2019; 14(12):e0225281. PubMed ID: 31800591 [TBL] [Abstract][Full Text] [Related]
6. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. Song K; Musci TJ; Caughey AB J Matern Fetal Neonatal Med; 2013 Aug; 26(12):1180-5. PubMed ID: 23356557 [TBL] [Abstract][Full Text] [Related]
7. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658 [TBL] [Abstract][Full Text] [Related]
8. Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions in Average-Risk Pregnancies: A Cost-Effectiveness Analysis. Xie X; Wang M; Goh ES; Ungar WJ; Little J; Carroll JC; Okun N; Huang T; Rousseau F; Dougan SD; Tu HA; Higgins C; Holubowich C; Sikich N; Dhalla IA; Ng V J Obstet Gynaecol Can; 2020 Jun; 42(6):740-749.e12. PubMed ID: 32008974 [TBL] [Abstract][Full Text] [Related]
9. Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions: A Health Technology Assessment. Health Quality Ontario Ont Health Technol Assess Ser; 2019; 19(4):1-166. PubMed ID: 30847010 [TBL] [Abstract][Full Text] [Related]
10. Clinical and Economic Impact of Adopting Noninvasive Prenatal Testing as a Primary Screening Method for Fetal Aneuploidies in the General Pregnancy Population. Kostenko E; Chantraine F; Vandeweyer K; Schmid M; Lefevre A; Hertz D; Zelle L; Bartha JL; Di Renzo GC Fetal Diagn Ther; 2019; 45(6):413-423. PubMed ID: 30130800 [TBL] [Abstract][Full Text] [Related]
11. Prenatal screening for fetal aneuploidy in singleton pregnancies. Chitayat D; Langlois S; Douglas Wilson R; ; J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752 [TBL] [Abstract][Full Text] [Related]
12. An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy Population. Benn P; Curnow KJ; Chapman S; Michalopoulos SN; Hornberger J; Rabinowitz M PLoS One; 2015; 10(7):e0132313. PubMed ID: 26158465 [TBL] [Abstract][Full Text] [Related]
13. Pregnancy outcome of autosomal aneuploidies other than common trisomies detected by noninvasive prenatal testing in routine clinical practice. Wan J; Li R; Zhang Y; Jing X; Yu Q; Li F; Li Y; Zhang L; Yi C; Li J; Li D; Liao C Prenat Diagn; 2018 Oct; 38(11):849-857. PubMed ID: 30078205 [TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA noninvasive prenatal screening for aneuploidy versus conventional screening: A systematic review of economic evaluations. Nshimyumukiza L; Menon S; Hina H; Rousseau F; Reinharz D Clin Genet; 2018 Jul; 94(1):3-21. PubMed ID: 29030960 [TBL] [Abstract][Full Text] [Related]
15. [Clinical application and evaluation of health economics for non-invasive prenatal testing of fetuses in Tianjin]. Ma R; Li X; Xu S; Shi Y; Ju D; Li Y; Meng F; Wang X; Du X; Xu N; Zhang Y Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Feb; 40(2):135-142. PubMed ID: 36709929 [TBL] [Abstract][Full Text] [Related]
16. Women's preference for non-invasive prenatal DNA testing versus chromosomal microarray after screening for Down syndrome: a prospective study. Cheng Y; Leung WC; Leung TY; Choy KW; Chiu R; Lo TK; Kwok KY; Sahota DS BJOG; 2018 Mar; 125(4):451-459. PubMed ID: 29125674 [TBL] [Abstract][Full Text] [Related]
17. Israeli Society of Medical Genetics NIPT Committee Opinion 072013: Non-invasive prenatal testing of cell-free DNA in maternal plasma for detection of fetal aneuploidy. Michaelson-Cohen R; Gershoni-Baruch R; Sharoni R; Shochat M; Yaron Y; Singer A Fetal Diagn Ther; 2014; 36(3):242-4. PubMed ID: 25138112 [TBL] [Abstract][Full Text] [Related]
18. The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis. Bayón JC; Orruño E; Portillo MI; Asua J Cost Eff Resour Alloc; 2019; 17():6. PubMed ID: 30867656 [TBL] [Abstract][Full Text] [Related]
19. Noninvasive prenatal testing in routine clinical practice--an audit of NIPT and combined first-trimester screening in an unselected Australian population. McLennan A; Palma-Dias R; da Silva Costa F; Meagher S; Nisbet DL; Scott F Aust N Z J Obstet Gynaecol; 2016 Feb; 56(1):22-8. PubMed ID: 26817523 [TBL] [Abstract][Full Text] [Related]
20. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. Saramago P; Yang H; Llewellyn A; Walker R; Harden M; Palmer S; Griffin S; Simmonds M Health Technol Assess; 2018 Mar; 22(13):1-172. PubMed ID: 29580376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]